Kenvue (KVUE)
Consumer Staples · Consumer Health / Over-the-Counter Healthcare
The world's largest pure-play consumer health company, leveraging a portfolio of iconic brands like Tylenol, Listerine, and Neutrogena across self-care, skin health, and essential health categories.
What Kenvue does
Kenvue is the world's largest pure-play consumer health company, operating a differentiated portfolio of over a century-old trusted brands including Aveeno, BAND-AID, Johnson's, Listerine, Neutrogena, Nicorette, Tylenol, and Zyrtec. The company serves consumers across Self Care, Skin Health and Beauty, and Essential Health products in over 165 countries. Kenvue combines scientific expertise, consumer insights, and digital capabilities to develop and market innovative health and wellness solutions, positioning itself at the intersection of healthcare and consumer goods.
Themes: ["Consumer health","Over-the-counter (OTC) medicines","Skincare and dermatology","Pain relief","Oral care","Digital transformation","Brand heritage and trust","Global consumer goods","Healthcare and wellness","Sustainable consumer health"]
Fundamentals
- Price$19.18 as of 2026-07-09 close
- Market cap$36.8B as of 2026-07-10
- 1-year return-6.8% as of 2026-07-09 close
- P/E22.70 as of 2026-07-10
- Net margin+10.6% as of 2026-07-10
- Gross margin+58.9% as of 2026-07-10
- ROE+15.2% as of 2026-07-10
- Debt / equity0.82 as of 2026-07-10
- Revenue growth (YoY)-0.1% as of 2026-07-10
- Revenue CAGR (3y)+0.2% SEC XBRL
- Beta0.45 as of 2026-07-10
Dividend: yield +4.3%; 3-year non-decreasing per-share dividend streak (SEC XBRL).
Key risks (from latest filing)
["Product safety, reliability, and efficacy concerns could trigger regulatory investigations, product recalls, facility shutdowns, and significant reputational damage and financial losses.","Heavy dependence on key retail customers and vulnerability to competitive pressure from private-label brands, generic products, and shifting consumer preferences could impact sales and market position.","Pending merger with Kimberly-Clark carries risks that expected synergies and benefits may not be realized, and integration could be delayed or unsuccessful; company also faces foreign regulatory approval requirements."]
Competitors & peers
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.